Fig. 3: ED treatment effect by prespecified subgroups. | Nature Communications

Fig. 3: ED treatment effect by prespecified subgroups.

From: Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial

Fig. 3

The primary outcome was the proportion of patients with mRS (0–2) at 90 ± 7 days. For subcategories, black squares represent point estimates (with the area of the square proportional to the number of events) and horizontal lines represent the 95% CI. NIHSS scores range from 0 to 42, with higher scores indicating more severe neurological deficits. For the NIHSS score, subgroups were dichotomized according to the median value. Abbreviations: ED edaravone dexborneol, mRS modified Rankin scale, NIHSS National Institutes of Health Stroke Scale. Source data are provided as a Source Data file.

Back to article page